Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 253

1.

Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy.

Tzeng CW, Fleming JB, Lee JE, Xiao L, Pisters PW, Vauthey JN, Abdalla EK, Wolff RA, Varadhachary GR, Fogelman DR, Crane CH, Balachandran A, Katz MH.

Ann Surg Oncol. 2012 Jun;19(6):2045-53. doi: 10.1245/s10434-011-2211-4. Epub 2012 Jan 19.

PMID:
22258816
2.

Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer.

Cooper AB, Holmes HM, des Bordes JK, Fogelman D, Parker NH, Lee JE, Aloia TA, Vauthey JN, Fleming JB, Katz MH.

J Am Coll Surg. 2014 Jul;219(1):111-20. doi: 10.1016/j.jamcollsurg.2014.02.023. Epub 2014 Mar 13.

PMID:
24856952
3.

Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.

Rose JB, Rocha FG, Alseidi A, Biehl T, Moonka R, Ryan JA, Lin B, Picozzi V, Helton S.

Ann Surg Oncol. 2014 May;21(5):1530-7. doi: 10.1245/s10434-014-3486-z. Epub 2014 Jan 29. Erratum in: Ann Surg Oncol. 2014 May;21(5):1538. Dosage error in article text.

PMID:
24473642
4.

Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter?

Chen KT, Devarajan K, Milestone BN, Cooper HS, Denlinger C, Cohen SJ, Meyer JE, Hoffman JP.

Ann Surg Oncol. 2014 Feb;21(2):662-9. doi: 10.1245/s10434-013-3396-5. Epub 2013 Nov 26.

PMID:
24276638
5.

Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.

Stokes JB, Nolan NJ, Stelow EB, Walters DM, Weiss GR, de Lange EE, Rich TA, Adams RB, Bauer TW.

Ann Surg Oncol. 2011 Mar;18(3):619-27. doi: 10.1245/s10434-010-1456-7. Epub 2011 Jan 7.

PMID:
21213060
6.

Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial.

Motoi F, Ishida K, Fujishima F, Ottomo S, Oikawa M, Okada T, Shimamura H, Takemura S, Ono F, Akada M, Nakagawa K, Katayose Y, Egawa S, Unno M.

Ann Surg Oncol. 2013 Nov;20(12):3794-801. doi: 10.1245/s10434-013-3129-9. Epub 2013 Jul 10.

PMID:
23838925
7.

Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma.

Homma Y, Taniguchi K, Murakami T, Nakagawa K, Nakazawa M, Matsuyama R, Mori R, Takeda K, Ueda M, Ichikawa Y, Tanaka K, Endo I.

Ann Surg Oncol. 2014 Feb;21(2):670-6. doi: 10.1245/s10434-013-3390-y. Epub 2013 Dec 6.

PMID:
24310792
8.

Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.

Roland CL, Yang AD, Katz MH, Chatterjee D, Wang H, Lin H, Vauthey JN, Pisters PW, Varadhachary GR, Wolff RA, Crane CH, Lee JE, Fleming JB.

Ann Surg Oncol. 2015 Apr;22(4):1168-75. doi: 10.1245/s10434-014-4192-6. Epub 2014 Oct 29.

PMID:
25352267
9.

Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial.

Golcher H, Brunner TB, Witzigmann H, Marti L, Bechstein WO, Bruns C, Jungnickel H, Schreiber S, Grabenbauer GG, Meyer T, Merkel S, Fietkau R, Hohenberger W.

Strahlenther Onkol. 2015 Jan;191(1):7-16. doi: 10.1007/s00066-014-0737-7. Epub 2014 Sep 25.

10.

Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.

Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Wang H, Cleary KR, Staerkel GA, Charnsangavej C, Lano EA, Ho L, Lenzi R, Abbruzzese JL, Wolff RA.

J Clin Oncol. 2008 Jul 20;26(21):3496-502. doi: 10.1200/JCO.2007.15.8634.

11.

Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy.

Barugola G, Partelli S, Crippa S, Capelli P, D'Onofrio M, Pederzoli P, Falconi M.

Am J Surg. 2012 Feb;203(2):132-9. doi: 10.1016/j.amjsurg.2011.03.008. Epub 2011 Aug 6.

PMID:
21824596
12.

Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?

Papalezova KT, Tyler DS, Blazer DG 3rd, Clary BM, Czito BG, Hurwitz HI, Uronis HE, Pappas TN, Willett CG, White RR.

J Surg Oncol. 2012 Jul 1;106(1):111-8. doi: 10.1002/jso.23044. Epub 2012 Feb 6.

PMID:
22311829
13.

Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation.

Estrella JS, Rashid A, Fleming JB, Katz MH, Lee JE, Wolf RA, Varadhachary GR, Pisters PW, Abdalla EK, Vauthey JN, Wang H, Gomez HF, Evans DB, Abbruzzese JL, Wang H.

Cancer. 2012 Jan 1;118(1):268-77. doi: 10.1002/cncr.26243. Epub 2011 Jul 6.

14.

Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation.

Chen J, Li D, Killary AM, Sen S, Amos CI, Evans DB, Abbruzzese JL, Frazier ML.

Ann Surg Oncol. 2009 Feb;16(2):431-9. doi: 10.1245/s10434-008-0220-8. Epub 2008 Nov 20.

PMID:
19020940
15.

Prognostic impact of CA 19-9 on outcome after neoadjuvant chemoradiation in patients with locally advanced pancreatic cancer.

Combs SE, Habermehl D, Kessel KA, Bergmann F, Werner J, Naumann P, Jäger D, Büchler MW, Debus J.

Ann Surg Oncol. 2014 Aug;21(8):2801-7. doi: 10.1245/s10434-014-3607-8. Epub 2014 Jun 11.

PMID:
24916745
16.

Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease.

Bickenbach KA, Gonen M, Tang LH, O'Reilly E, Goodman K, Brennan MF, D'Angelica MI, Dematteo RP, Fong Y, Jarnagin WR, Allen PJ.

Ann Surg Oncol. 2012 May;19(5):1663-9. doi: 10.1245/s10434-011-2156-7. Epub 2011 Dec 1.

PMID:
22130621
17.

Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma.

Van Buren G 2nd, Ramanathan RK, Krasinskas AM, Smith RP, Abood GJ, Bahary N, Lembersky BC, Shuai Y, Potter DM, Bartlett DL, Zureikat AH, Zeh HJ, Moser AJ.

Ann Surg Oncol. 2013 Nov;20(12):3787-93. doi: 10.1245/s10434-013-3161-9. Epub 2013 Aug 1.

PMID:
23904005
18.

Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?

Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, Kelly T, Erickson B, Wang H, Evans DB, George B.

Oncologist. 2014 Mar;19(3):266-74. doi: 10.1634/theoncologist.2013-0273. Epub 2014 Feb 25.

19.

Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma.

Boone BA, Steve J, Zenati MS, Hogg ME, Singhi AD, Bartlett DL, Zureikat AH, Bahary N, Zeh HJ 3rd.

Ann Surg Oncol. 2014 Dec;21(13):4351-8. doi: 10.1245/s10434-014-3842-z. Epub 2014 Aug 5.

PMID:
25092157
20.

Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience.

Leone F, Gatti M, Massucco P, Colombi F, Sperti E, Campanella D, Regge D, Gabriele P, Capussotti L, Aglietta M.

Cancer. 2013 Jan 15;119(2):277-84. doi: 10.1002/cncr.27736. Epub 2012 Jul 6.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk